Show simple item record

dc.contributor.authorRivera-Hernandez, Tania
dc.contributor.authorPandey, Manisha
dc.contributor.authorHenningham, Anna
dc.contributor.authorCole, Jason
dc.contributor.authorChoudhury, Biswa
dc.contributor.authorCork, Amanda J
dc.contributor.authorGillen, Christine M
dc.contributor.authorGhaffar, Khairunnisa Abdul
dc.contributor.authorWest, Nicholas P
dc.contributor.authorSilvestri, Guido
dc.contributor.authorGood, Michael F
dc.contributor.authorMoyle, Peter M
dc.contributor.authorToth, Istvan
dc.contributor.authorNizet, Victor
dc.contributor.authorBatzloff, Michael R
dc.contributor.authorWalker, Mark J
dc.date.accessioned2017-08-31T12:30:39Z
dc.date.available2017-08-31T12:30:39Z
dc.date.issued2016
dc.identifier.issn2150-7511
dc.identifier.doi10.1128/mBio.00618-16
dc.identifier.urihttp://hdl.handle.net/10072/100373
dc.description.abstractGroup A Streptococcus (GAS) is an important human pathogen responsible for both superficial infections and invasive diseases. Autoimmune sequelae may occur upon repeated infection. For this reason, development of a vaccine against GAS represents a major challenge, since certain GAS components may trigger autoimmunity. We formulated three combination vaccines containing the following: (i) streptolysin O (SLO), interleukin 8 (IL-8) protease (Streptococcus pyogenes cell envelope proteinase [SpyCEP]), group A streptococcal C5a peptidase (SCPA), arginine deiminase (ADI), and trigger factor (TF); (ii) the conserved M-protein-derived J8 peptide conjugated to ADI; and (iii) group A carbohydrate lacking the N-acetylglucosamine side chain conjugated to ADI. We compared these combination vaccines to a “gold standard” for immunogenicity, full-length M1 protein. Vaccines were adjuvanted with alum, and mice were immunized on days 0, 21, and 28. On day 42, mice were challenged via cutaneous or subcutaneous routes. High-titer antigen-specific antibody responses with bactericidal activity were detected in mouse serum samples for all vaccine candidates. In comparison with sham-immunized mice, all vaccines afforded protection against cutaneous challenge. However, only full-length M1 protein provided protection in the subcutaneous invasive disease model.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherAmerican Society for Microbiology
dc.relation.ispartofpagefrome00618-16-1
dc.relation.ispartofpagetoe00618-16-9
dc.relation.ispartofissue3
dc.relation.ispartofjournalmBio
dc.relation.ispartofvolume7
dc.subject.fieldofresearchMicrobiology
dc.subject.fieldofresearchMicrobiology not elsewhere classified
dc.subject.fieldofresearchcode3107
dc.subject.fieldofresearchcode310799
dc.titleDiffering Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttp://creativecommons.org/licenses/by/4.0/
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2016 Rivera-Hernandez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
gro.hasfulltextFull Text
gro.griffith.authorBatzloff, Michael R.
gro.griffith.authorPandey, Manisha
gro.griffith.authorGood, Michael F.
gro.griffith.authorRivera-Hernandez, Tania
gro.griffith.authorWest, Nic P.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record